As of Jan 10, 2025, United Therapeutics Corporation's fair value using the Peter Lynch formula is $438.0 per share. The current price of $365.0 suggests United Therapeutics Corporation may be undervalued by this metric.
As of Jan 10, 2025, United Therapeutics Corporation's P/E ratio is 14.6x. This is calculated by dividing the current share price of $365.0 by the Earnings per Share (EPS) for the trailing twelve months, which is $24.3. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
United Therapeutics Corporation earnings per share (EPS) for the twelve months ending Jan 10, 2025, was $24.3, a 17.5% growth year-over-year.